SAGE-547
Phase 2Small molecule
Supernus Pharmaceuticals, Inc.SAGE-547 is one of 90 small molecule programs targeting Postpartum Depression. It is currently in Phase 2.
3
Indications
8
Total Trials
0
Active Trials
89
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
50 competitors in Postpartum Depression
#DrugCompanyPhaseTrials
1Zulresso
BiogenApproved
Estrace
Novo NordiskApproved
Zoloft
VViatris Specialty LLC
Approved
Ketalar
AAultman Health Foundation
Approved
Sufenta
LLeaf Vertical Inc.
Approved
Naropin
FFresenius Kabi Oncology Ltd.
Approved
Dilaudid
RRhodes Pharmaceuticals, L.P.
Approved
Ultram
WWim Janssens
Approved
Prometrium
FerringApproved
Celebrex
PPhiladelphia Eye Associates
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Postpartum Depression4 trials
Status Epilepticus3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SAGE-547. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details